Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B-Reference-Cited by-同舟云学术

Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B

Published:2021-09-04 Issue:11 Volume:28 Page:1570-1578
ISSN:1352-0504
Container-title:Journal of Viral Hepatitis
language:en
Short-container-title:J Viral Hepat

Author:

Lee Hye Won¹²³^ORCID,Cho Young Youn⁴,Lee Hyein³^ORCID,Lee Jae Seung¹²³^ORCID,Kim Seung Up¹²³^ORCID,Park Jun Yong¹²³^ORCID,Kim Do Young¹²³,Ahn Sang Hoon¹²³,Kim Beom Kyung¹²³^ORCID,Park Soo Young⁵

Affiliation:

1. Department of Internal Medicine Yonsei University College of Medicine Seoul Republic of Korea

2. Institute of Gastroenterology Yonsei University College of Medicine Seoul Republic of Korea

3. Yonsei Liver Center Severance Hospital, Yonsei University Health System Seoul Republic of Korea

4. Department of Internal Medicine Chung Ang University College of Medicine Seoul Republic of Korea

5. Department of Internal Medicine Kyungpook National University School of Medicine Daegu Republic of Korea

Publisher

Wiley

Subject

Virology,Infectious Diseases,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.13601

Reference47 articles.

1. Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017

2. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop

3. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection

4. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

5. KASL clinical practice guidelines for liver cirrhosis: Varices, hepatic encephalopathy, and related complications

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B;Journal of Gastroenterology and Hepatology;2024-05

2. Risk of hepatocellular carcinoma after curative treatment when switching from tenofovir disoproxil fumarate or entecavir to tenofovir alafenamide: A real‐world multicenter cohort study;Hepatology Research;2024-02

3. Noninferiority Outcomes of Besifovir Compared to Tenofovir Alafenamide in Treatment-Naïve Patients with Chronic Hepatitis B;Gut and Liver;2024-01-12

4. Are the New Nucleos(t)ide Analogs Better than the Old Nucleos(t)ide Analogs?;Clinics in Liver Disease;2023-11

5. On-treatment risks of cirrhosis and hepatocellular carcinoma among a large cohort of predominantly non-Asian patients with non-cirrhotic chronic hepatitis B;JHEP Reports;2023-10